At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Metformin & Entecavir +1 moredrug
Likely dose
Metformin & Entecavir 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial
In Brief
A clinical study evaluating Metformin & Entecavir and Placebo & Entecavir for Chronic Hepatitis B. Completed, enrolled 60 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of metformin as add-on to entecavir therapy in patients with chronic hepatitis B.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesChina
CollaboratorsJinan Military General Hospital
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMar 2020
Primary CompletionJul 2021
Study CompletionSep 2021
TodayJul 2026
First PostedDec 2, 2019
Enrollment StartMar 13, 2020
Primary CompletionJul 2, 2021
Study CompletionSep 13, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.6 years ago
Interventions
Metformin & Entecavirdrug
Adding sustained-release metformin hydrochloride (1000 mg, oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)
Placebo & Entecavirdrug
Adding placebo (oral, once a day) for 24 weeks to the ongoing entecavir therapy (0.5 mg, oral, once a day)